Genmab — August 2019

[Sukkeralf]

Nothing about the BCMA/CD3 antibody?

[E_L]

FP-149
Safety of rapid daratumumab infusion in
relapsed and refractory multiple myeloma

[E_L]

Daratumumab infusion
time of 90 minutes was well tolerated, thus allowing
a considerable saving of time for RRMM patients
and potentially ameliorating their adherence to
treatment

[E_L]

i am still searching for interesting Dara hits, there are 289 in that book, so bear with me

[Solsen]

The AMG420 are also in the abstracts although it seems to be stopped.

[E_L]

FP-155
DNA methyltransferase inhibitors upregulate
CD38 expression and enhance daratumumab
efficacy in multiple myeloma

[E_L]

Summary and Conclusions: Our
results here demonstrate that inhibiting DNMTs
leads to CD38 upregulation and increased
vulnerability to Daratumumab treatment. We
propose that combination treatment with

[E_L]

Azacytidine and Daratumumab can lead to higher
efficacy of daratumumab in daratumumab-naïve
MM, as well as reversal of daratumumab-resistance.
We are currently planning a clinical trial to test this
hypothesis.

[E_L]

a bit like ATRA as we have seen before? i expect more and more trials based on Dara by other firms

[Bulder]

In my notes I have 5 other drugs supporting c38 expression. ATRA, Sepantronium bromide (YM155), Panobinostat og SY-1425 (tamibarotene) and Inecalcitol. This must be no 6. I think ATRA has been given up more or less?

[E_L]

your notes are better then mine I think there is still an ATRA-Dara trial open, but indeed, Jan at some point said there are better options

[E_L]

ATRA was a bit toxic, wasnt it

[E_L]

FP-162 says costs associated with
rapid infusion vs normal infusion do not differ much. I am a bit surprised by that.

[E_L]

Total costs estimated
for the standard rate was $137,200 and $122,200 for
the rapid rate

[Bulder]

Once again: Thanks for the tremendous job you are doing, E L, for the benefit of us all.

[Bella1]

[E_L]

lol, almost done with this document

[E_L]

did not know this combo yet? SP-142
Multi-agent therapy with pomalidomide,
bortezomib, doxorubicin, dexamethasone and
daratumumab (Pom-PAD-Dara) in relapsed/
refractory multiple myeloma

[E_L]

SP-201
Changes in cardiac biomarkers with
daratumumab therapy in patients with light
chain amyloidosis

[E_L]

Discussion: Our results show that dara treatment
rapidly lowered dFLC without worsening cardiac
biomarkers in AL...., dara does not
impart additional AL cardiac biomarker toxicity.
Thus, particularly among advanced cardiac patients,
dara should be considered as an early treatment.